Base Pair Biotechnologies is an influential driver of the aptamer field; an expanding field that Markets and Markets predicts will be worth $2.1 billion by 2018 – up from $287 million in 2013. For more than a decade the scientific team has been advancing the selection and development process, initially studying aptamers on a research basis. Several years ago, as patent restrictions lifted, the team commercialized their service and began partnering on diverse and challenging projects. Through this, they are now advancing the publics’ perception of what aptamers can achieve.
Base Pair is committed to collaboration and delivering success through knowledge and diligence. Determined to make aptamers more accessible, they also crafted a business model that expands project and financing options. Overall efficiency and low costs are boosted by patented multiplex technology, which allows many targets to be run in tandem.
Base Pair Biotechnologies, Inc. is a spin-off of parent company, BioTex, Inc., the original developer of several molecular biology and diagnostic technologies currently being commercialized. Base Pair Bio is a privately held company located in the Med Center of Houston, Texas.